With the successful completion of the Phase 1b trial, these data are informing the design of a multi-center Phase 2b prospective randomized placebo-controlled at a 2:1 accrual rate. We are targeting early 2021.
News
Stay informed about our latest
news and developments.
By accessing our website or software provided by our third-party vendors, you consent to accept cookies, (including other identifiers). These include pieces of text that are stored on your computer or device. This site uses cookies and Google Analytics to improve navigation, minimize the need to reenter information previously entered on forms, personalize messages, and collect statistical information to improve site navigation and provide content of greatest interest to users.Ok